112 related articles for article (PubMed ID: 17589297)
1. Reduced intensity transplantation for metastatic renal cell cancer with 2-year follow-up.
Peres E; Abidi MH; Mellon-Reppen S; Klein J; Braun T; Abella E; Dansey R
J Immunother; 2007; 30(5):562-6. PubMed ID: 17589297
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
[TBL] [Abstract][Full Text] [Related]
3. Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation.
Childs R; Chernoff A; Contentin N; Bahceci E; Schrump D; Leitman S; Read EJ; Tisdale J; Dunbar C; Linehan WM; Young NS; Barrett AJ
N Engl J Med; 2000 Sep; 343(11):750-8. PubMed ID: 10984562
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic stem-cell transplantation of renal cell cancer after nonmyeloablative chemotherapy: feasibility, engraftment, and clinical results.
Rini BI; Zimmerman T; Stadler WM; Gajewski TF; Vogelzang NJ
J Clin Oncol; 2002 Apr; 20(8):2017-24. PubMed ID: 11956260
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: single institution experience with a minimum 1-year follow-up.
Nakagawa T; Kami M; Hori A; Kim SW; Murashige N; Hamaki T; Kishi Y; Fujimoto H; Matsuoka N; Okajima E; Komiyama M; Tobisu K; Wakayama T; Uike N; Tajima K; Makimoto A; Mori S; Tanosaki R; Takaue Y; Kakizoe T
Exp Hematol; 2004 Jul; 32(7):599-606. PubMed ID: 15246155
[TBL] [Abstract][Full Text] [Related]
6. Nonmyeloablative stem cell transplantation in metastatic renal cell carcinoma: delayed graft-versus-tumor effect is associated with chimerism conversion but transplantation has high toxicity.
Massenkeil G; Roigas J; Nagy M; Wille A; Stroszczynski C; Mapara MY; Loening S; Dörken B; Arnold R
Bone Marrow Transplant; 2004 Aug; 34(4):309-16. PubMed ID: 15220955
[TBL] [Abstract][Full Text] [Related]
7. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T; Woolfrey A; Georges G; Kiem HP; Zaucha JM; Blume KG; Shizuru J; Niederwieser D; Storb R
Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic non-myeloablative hematopoietic stem cell transplantation for treatment of metastatic renal cell carcinoma -- single center experience.
Rzepecki P; Zolnierek J; Sarosiek T; Langiewicz P; Szczylik C
Neoplasma; 2005; 52(3):238-42. PubMed ID: 15875086
[TBL] [Abstract][Full Text] [Related]
9. Nonmyeloablative transplants: preclinical and clinical results.
Sandmaier BM; McSweeney P; Yu C; Storb R
Semin Oncol; 2000 Apr; 27(2 Suppl 5):78-81. PubMed ID: 10877058
[TBL] [Abstract][Full Text] [Related]
10. Allogeneic haematopoietic stem cell transplantation for metastatic renal carcinoma in Europe.
Barkholt L; Bregni M; Remberger M; Blaise D; Peccatori J; Massenkeil G; Pedrazzoli P; Zambelli A; Bay JO; Francois S; Martino R; Bengala C; Brune M; Lenhoff S; Porcellini A; Falda M; Siena S; Demirer T; Niederwieser D; Ringdén O;
Ann Oncol; 2006 Jul; 17(7):1134-40. PubMed ID: 16648196
[TBL] [Abstract][Full Text] [Related]
11. Adoptive immunotherapy by allogeneic stem cell transplantation for metastatic renal cell carcinoma: a CALGB intergroup phase II study.
Rini BI; Halabi S; Barrier R; Margolin KA; Avigan D; Logan T; Stadler WM; McCarthy PL; Linker CA; Small EJ; ; ;
Biol Blood Marrow Transplant; 2006 Jul; 12(7):778-85. PubMed ID: 16785067
[TBL] [Abstract][Full Text] [Related]
12. Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect.
Childs RW; Clave E; Tisdale J; Plante M; Hensel N; Barrett J
J Clin Oncol; 1999 Jul; 17(7):2044-9. PubMed ID: 10561256
[TBL] [Abstract][Full Text] [Related]
13. Reduced-intensity conditioning allogeneic transplantation from unrelated donors: evaluation of mycophenolate mofetil plus cyclosporin A as graft-versus-host disease prophylaxis.
Pérez-Simón JA; Martino R; Caballero D; Valcarcel D; Rebollo N; de la Cámara R; de Oteiza JP; Heras I; Calvo MV; Sierra J; San Miguel JF;
Biol Blood Marrow Transplant; 2008 Jun; 14(6):664-71. PubMed ID: 18489992
[TBL] [Abstract][Full Text] [Related]
14. [Quadruple therapy with CsA, MTX, MMF and ATG for preventing graft-versus-host disease in unrelated donor hematopoietic stem cell transplantation].
Liu QF; Sun J; Zhang Y; Xu D; Liu XL; Xu B; Meng FY; Zhou SY
Di Yi Jun Yi Da Xue Xue Bao; 2003 Nov; 23(11):1143-5. PubMed ID: 14625172
[TBL] [Abstract][Full Text] [Related]
15. Haemopoietic stem-cell transplantation with antibody-based minimal-intensity conditioning: a phase 1/2 study.
Straathof KC; Rao K; Eyrich M; Hale G; Bird P; Berrie E; Brown L; Adams S; Schlegel PG; Goulden N; Gaspar HB; Gennery AR; Landais P; Davies EG; Brenner MK; Veys PA; Amrolia PJ
Lancet; 2009 Sep; 374(9693):912-20. PubMed ID: 19729196
[TBL] [Abstract][Full Text] [Related]
16. The impact of graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic stem cell transplant in acute myeloid leukemia: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Rubio MT; Labopin M; Blaise D; Socié G; Contreras RR; Chevallier P; Sanz MA; Vigouroux S; Huynh A; Shimoni A; Bulabois CE; Caminos N; López-Corral L; Nagler A; Mohty M
Haematologica; 2015 May; 100(5):683-9. PubMed ID: 25769546
[TBL] [Abstract][Full Text] [Related]
17. Stable long-term donor engraftment following reduced-intensity hematopoietic cell transplantation for sickle cell disease.
Krishnamurti L; Kharbanda S; Biernacki MA; Zhang W; Baker KS; Wagner JE; Wu CJ
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1270-8. PubMed ID: 18940682
[TBL] [Abstract][Full Text] [Related]
18. Unrelated donor transplantation after reduced intensity conditioning as an approach for patients lacking related donors for allogeneic stem cell transplantation.
Hoepfner S; Goerner M; Benner A; Henning P; Ho AD
J Hematother Stem Cell Res; 2003 Jun; 12(3):331-9. PubMed ID: 12857374
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.
Pedrazzoli P; Da Prada GA; Giorgiani G; Schiavo R; Zambelli A; Giraldi E; Landonio G; Locatelli F; Siena S; Della Cuna GR
Cancer; 2002 May; 94(9):2409-15. PubMed ID: 12015766
[TBL] [Abstract][Full Text] [Related]
20. Low-intensity conditioning and hematopoietic stem cell transplantation in patients with renal and colon carcinoma.
Hentschke P; Barkholt L; Uzunel M; Mattsson J; Wersäll P; Pisa P; Martola J; Albiin N; Wernerson A; Söderberg M; Remberger M; Thörne A; Ringdén O
Bone Marrow Transplant; 2003 Feb; 31(4):253-61. PubMed ID: 12621459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
